Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | carboxylesterase 5A | 0.2236 | 0.8125 | 0.8366 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.2236 | 0.8125 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.2236 | 0.8125 | 0.8366 |
Loa Loa (eye worm) | hypothetical protein | 0.2236 | 0.8125 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1918 | 0.6567 | 0.7443 |
Loa Loa (eye worm) | carboxylesterase | 0.2236 | 0.8125 | 1 |
Schistosoma mansoni | poly [ADP-ribose] polymerase | 0.1384 | 0.3951 | 0.1413 |
Echinococcus granulosus | acetylcholinesterase | 0.2236 | 0.8125 | 0.8366 |
Echinococcus multilocularis | acetylcholinesterase | 0.2236 | 0.8125 | 0.8538 |
Echinococcus granulosus | poly adp ribose polymerase 2 | 0.1384 | 0.3951 | 0.3464 |
Brugia malayi | Carboxylesterase family protein | 0.2236 | 0.8125 | 0.75 |
Echinococcus multilocularis | poly (adp ribose) polymerase 2 | 0.1384 | 0.3951 | 0.4152 |
Echinococcus multilocularis | poly (ADP ribose) polymerase 1 | 0.252 | 0.9517 | 1 |
Trypanosoma cruzi | poly(ADP-ribose) polymerase, putative | 0.1384 | 0.3951 | 0.5 |
Schistosoma mansoni | poly [ADP-ribose] polymerase | 0.252 | 0.9517 | 1 |
Echinococcus multilocularis | acetylcholinesterase | 0.2236 | 0.8125 | 0.8538 |
Entamoeba histolytica | poly(ADP-ribose) polymerase, putative | 0.252 | 0.9517 | 0.5 |
Brugia malayi | Carboxylesterase family protein | 0.2236 | 0.8125 | 0.75 |
Brugia malayi | WGR domain containing protein | 0.252 | 0.9517 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.2236 | 0.8125 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.2236 | 0.8125 | 0.8538 |
Echinococcus granulosus | poly ADP ribose polymerase 1 | 0.252 | 0.9517 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1384 | 0.3951 | 0.3149 |
Trypanosoma cruzi | poly(ADP-ribose) polymerase, putative | 0.1384 | 0.3951 | 0.5 |
Trypanosoma brucei | poly(adp-ribose) polymerase | 0.1384 | 0.3951 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.2236 | 0.8125 | 0.7853 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 69.6 % | Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed reduction in catalepsy at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 30 to 180 min | ChEMBL. | No reference |
TIME (functional) | = 25 s | Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed as decrease in mean descent time at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 30 min | ChEMBL. | No reference |
TIME (functional) | = 31 s | Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed as decrease in mean descent time at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 60 min | ChEMBL. | No reference |
TIME (functional) | = 49 s | Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed as decrease in mean descent time at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 90 min | ChEMBL. | No reference |
TIME (functional) | = 92 s | Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed as decrease in mean descent time at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 120 min | ChEMBL. | No reference |
TIME (functional) | = 123 s | Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed as decrease in mean descent time at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 150 min | ChEMBL. | No reference |
TIME (functional) | = 178 s | Antiparkinsonian activity against haloperidol-induced catalepsy in Mus musculus Swiss albino (mouse) assessed as decrease in mean descent time at 100 mg/kg, ip administered 30 min prior to haloperidol injection measured after 180 min | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.